Mr. Lankau is an experienced bio-pharmaceutical executive with over 30 years of management experience in developing and commercializing pharmaceutical products. He is a Principal in Lankau Consulting LLC, which has been providing advisory and consulting services since 2014.
Mr. Lankau is a Member of the Board of Directors for Cipla Limited, one of the top pharmaceutical companies in India whose goal is to ensure that no patient shall be denied access to high quality & affordable medicine and support. Cipla is a leading global healthcare company which uses innovation and technology to meet everyday patient needs.
Mr. Lankau is a member of the Board of Directors of InvaGen Pharmaceuticals, Inc., a leading generic pharmaceutical company, engaged in development, manufacturing, marketing and distributing generic pharmaceuticals, with focus on a wide range of therapeutic areas including, cardiovascular, anti-infective, CNS, anti-inflammatory, anti-diabetic and anti-depressants.
He is also a Member of the Board of Directors of Quion Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing products that help address major societal issues including the opioid epidemic and the military veteran suicide rate.
Mr. Lankau previously served as a Member of the Board of Directors , and was formerly Chairman of the Board, of Phosphagenics Limited, an Australian research-based biotechnology company that discovers and develops novel approaches to enhance the delivery, effectiveness, and/or tolerability of proven pharmaceutical, consumer, and animal health products, until his retirement in 2018.
Mr. Lankau was also most recently a Member of the Board of Directors for ANI Pharmaceuticals, Inc., an integrated specialty and generic pharmaceutical company developing, manufacturing and marketing branded and generic prescription products, until his retirement in 2017.
Additionally, he serves on the Board of Advisors for Orchard Venture Partners, a life sciences venture capital firm.
Mr. Lankau was Executive Chairman of the Board for Nautilus Neurosciences, Inc., a commercial stage, private equity-backed, neurology-focused specialty pharmaceutical company, which sold its business to Depomed, Inc. in December 2013. He was responsible for the overall management of the company and directed the transaction process which resulted in the negotiation and sale of the company’s assets.
He is the former Chairman and CEO of Logical Therapeutics, Inc., a venture capital backed development stage biopharmaceutical company which developed compounds to improve the gastrointestinal tolerability of NSAID’s in the chronic treatment of inflammatory disease. He directed all aspects for the pre-clinical and clinical development including FDA submissions.
Prior to Logical, he was the President and CEO of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company. He previously served as the company’s President and Chief Operating Officer and as Senior Vice President, US Commercial Business. While CEO, he lead the company to become an industry leader in specialty pharma, as well as developing its pipeline which included 12 product acquisitions and/or licensing transactions. He was also a member of its Board of Directors.
Prior to Endo, Mr. Lankau was Vice President, Sales and Marketing for Alpharma, Inc. He began his pharmaceutical career with Rhone-Poulenc Rorer, Inc. (now Sanofi) in multiple commercial roles, and had most recently been Vice President, Sales-US Pharmaceuticals.
Mr. Lankau can be reached directly at firstname.lastname@example.org.
Lankau Consulting has a network of well regarded pharmaceutical experts that it deploys in project services work, where the engagement calls for more functional expertise with content specific knowledge and experience. These areas include: